Uric Acid (UA) has been related to the development of fatal and non-fatal Cardio-Vascular (CV) events in the general population [1] as well as in patients experiencing an Acute Coronary Syndromes (ACS) [2] and in those affected by Heart Failure (HF) [3]. In this latter group, results were also confirmed in the context of acute decompensated HF with a significant relationship between UA, measured at the time of admission, and subsequent long-term mortality and re-hospitalization [4]. Furthermore, UA was also associated with the development of new-onset HF [5] and with a lower Left Ventricular Ejection Fraction (LVEF) and exercise capacity and a higher NYHA class [6].
